last
year
emerg
infecti
diseas
captur
attent
transfus
medicin
commun
emerg
diseas
broadli
defin
whose
rate
increas
last
two
decad
blood
safeti
perspect
current
attent
larg
focus
recent
emerg
agent
may
transmit
transfus
europ
particularli
uk
measur
implement
address
concern
regard
potenti
transmiss
prion
associ
variant
diseas
vcjd
recent
emerg
continu
spread
west
nile
viru
usa
led
rapid
implement
nucleic
acid
test
nat
reduc
incid
transfus
transmiss
lastli
follow
emerg
sever
acut
respiratori
syndrom
sar
blood
collect
agenc
test
manufactur
rapidli
develop
measur
address
potenti
transmiss
coronaviru
yet
measur
fortun
requir
implement
transfus
medicin
focus
recent
emerg
agent
sever
agent
first
describ
decad
ago
repres
ongo
blood
safeti
risk
adequ
address
respect
continu
fli
radar
perhap
foremost
among
agent
sever
speci
babesia
known
caus
human
infect
first
case
human
babesiosi
also
fatal
report
known
yugoslavia
first
us
case
report
nantucket
island
new
england
coast
sinc
hundr
case
human
babesiosi
report
usa
addit
case
report
europ
known
geograph
rang
parasit
continu
expand
owe
environment
ecolog
chang
enhanc
epidemiolog
investig
overal
increas
public
health
awar
blood
safeti
perspect
infect
involv
babesia
spp
becom
increasingli
problemat
usa
progress
report
year
howev
despit
epidemiolog
data
suggest
babesia
spp
grow
blood
safeti
concern
particularli
usa
continu
overshadow
often
newli
emerg
agent
review
attempt
summar
babesia
spp
remain
neglect
blood
safeti
concern
also
consid
prioriti
transfus
medicin
human
infect
babesia
spp
primarili
attribut
two
speci
b
microti
b
divergen
tabl
b
microti
predomin
found
northeastern
upper
midwestern
usa
also
endem
europ
addit
b
agent
identifi
recent
europ
japan
part
asia
suggest
wider
dissemin
b
divergen
mainli
limit
europ
three
zoonot
case
usa
attribut
b
organ
bear
nearli
ident
ribosom
rna
gene
sequenc
similar
score
european
parasit
howev
past
decad
also
seen
emerg
agent
implic
human
diseas
least
two
infect
phylogenet
distinct
b
microti
b
divergen
agent
often
design
geograph
locat
includ
california
washington
austria
itali
sporad
case
human
babesiosi
report
egypt
south
africa
mexico
aetiolog
agent
fulli
character
taken
togeth
seem
like
new
agent
broaden
geograph
distribut
babesia
spp
continu
report
babesiosi
zoonot
diseas
maintain
natur
complex
interact
tick
vector
anim
reservoir
maintenancetransport
host
worldwid
primari
vector
babesia
spp
tick
genu
ixod
usa
tick
scapulari
synonym
dammini
serv
primari
vector
b
microti
pacificu
thought
vector
european
vector
b
microti
triangulicep
tick
feed
human
perhap
explain
human
case
b
microti
report
europ
sheep
tick
ricinu
also
shown
compet
vector
b
microti
tick
primarili
recogn
european
vector
b
divergen
locat
implic
ixod
tick
vector
babesia
vector
local
transmit
borrelia
burgdorferi
aetiolog
agent
lyme
diseas
tick
vector
b
agent
japan
definit
identifi
analog
describ
persulcatu
japanes
vector
lyme
borreliosi
tick
adult
nymphal
stage
capabl
transmit
infect
howev
instanc
tick
must
feed
h
longer
success
transmit
parasit
also
critic
parasit
life
cycl
reservoir
transport
host
babesia
infect
human
rodent
insectivor
act
reservoir
host
critic
maintain
infect
wild
primari
us
reservoir
host
b
microti
mous
peromyscu
leucopu
may
also
serv
reservoir
also
play
critic
role
usa
deer
compet
host
b
microti
serv
transport
host
adult
scapulari
analog
reservoir
host
japan
probabl
field
mous
apodemu
speciosu
first
shown
infect
b
parasit
year
ago
contrast
throughout
distribut
b
divergen
europ
cattl
serv
reservoir
host
human
infect
well
definit
host
parasit
babesi
infect
demonstr
spectrum
diseas
rang
asymptomat
sever
ill
influenc
infect
speci
tick
vector
deposit
thousand
infect
sporozoit
dermi
latter
stage
feed
ie
h
within
human
host
sporozoit
infect
erythrocyt
becom
trophozoit
replic
binari
fission
produc
characterist
maltes
cross
form
seen
case
eg
replic
turn
lead
cell
ruptur
lysi
releas
merozoit
infect
addit
erythrocyt
replic
cycl
produc
high
level
parasitemia
haemoglobinuria
within
host
asymptomat
diseas
uncommon
infect
b
microti
often
goe
undetect
symptomat
infect
b
microti
gener
mild
produc
symptom
appear
week
postinfect
characterist
symptom
includ
fever
headach
chill
drench
sweat
myalgia
malais
usual
abat
within
week
sever
diseas
complic
includ
haemolyt
anaemia
thrombocytopenia
haematuria
renal
failur
observ
infant
elderli
asplen
immunocompromis
patient
parasitaemia
level
particularli
among
asplen
patient
approach
result
sever
even
anaemia
usa
mortal
rate
clinic
appar
b
microti
infect
almost
infect
b
divergen
gener
sever
often
produc
fulmin
infect
date
case
human
babesiosi
caus
b
divergen
report
europ
case
patient
asplen
symptom
appear
rapidli
week
postinfect
character
haemoglobinuria
follow
jaundic
result
sever
haemolysi
sever
infect
coupl
asplenia
contribut
mortal
rate
b
divergen
also
appear
virul
b
microti
produc
sever
diseas
even
immunocompet
patient
unlik
infect
b
divergen
b
microti
also
demonstr
chronic
one
studi
parasitaemia
shown
persist
month
base
posit
polymeras
chain
reaction
pcr
result
recent
studi
corrobor
presenc
parasitaemia
among
blood
donor
antibodi
b
microti
case
persist
month
howev
latter
studi
also
demonstr
patient
infect
b
microti
produc
elev
antibodi
titr
absenc
measur
parasitaemia
suggest
patient
maintain
chronic
babesi
infect
limit
detect
pcr
parasit
may
circul
peripher
blood
extrem
low
number
intermitt
basi
may
restrict
sequest
tissu
organ
site
inde
recrudesc
measur
parasitaemia
among
serolog
posit
patient
report
sever
instanc
absenc
obviou
infect
vector
thu
possibl
indic
underli
silent
infect
observ
support
earlier
content
gorenflot
et
al
suggest
immunocompet
peopl
may
act
asymptomat
carrier
babesiosi
altern
suggest
chronic
infect
associ
babesia
spp
may
link
parasit
abil
undergo
antigen
variat
express
cell
surfac
infect
erythrocyt
antigen
variat
implic
evas
strategi
b
microti
parasit
consider
allel
polymorph
may
allow
frequent
recombin
event
lead
mix
infect
therebi
allow
parasit
evad
recognit
immun
respons
diagnosi
babesiosi
part
reli
upon
symptomatolog
describ
natur
symptom
often
make
accur
clinic
diagnosi
difficult
addit
diagnost
inform
obtain
assess
risk
factor
includ
detail
travel
area
recent
blood
transfus
splenectomi
exposur
tick
unfortun
peopl
infect
diseas
recal
associ
tick
bite
thu
diagnost
assay
play
crucial
role
identifi
infect
babesia
spp
case
direct
detect
infect
possibl
examin
thin
thick
blood
smear
stain
wright
giemsa
stain
red
cell
contain
merozoit
howev
infect
parasitaemia
level
fall
well
limit
visual
detect
detect
smear
also
labour
intens
subject
natur
easili
misinterpret
owe
similar
ring
form
plasmodium
falciparum
direct
detect
enhanc
inocul
suscept
rodent
hamster
mice
b
microti
inocul
gerbil
b
divergen
patient
blood
babesia
spp
readili
replic
appropri
rodent
host
thu
amplifi
infect
identifi
smear
rodent
blood
howev
anim
must
check
period
period
make
techniqu
impract
rapid
diagnosi
serolog
assay
detect
immunoglobulin
igm
immunoglobulin
g
igg
provid
reliabl
altern
direct
detect
divergen
infect
rapid
onset
symptom
eg
haemoglobinuria
associ
b
divergen
make
serolog
detect
impract
mani
patient
infect
may
prove
fatal
detect
antibodi
present
gold
standard
serolog
detect
b
microti
infect
immunofluoresc
assay
ifa
use
infect
rodent
red
cell
antigen
sourc
presenc
igm
indic
recent
acut
infect
failur
demonstr
igg
subsequ
sampl
may
suggest
result
igm
present
acut
phase
diseas
igg
persist
month
sometim
year
critic
success
identif
babesi
infect
use
appropri
antigen
sourc
agent
exampl
sera
patient
washington
state
recent
b
infect
react
b
microti
antigen
show
mark
ifa
reactiv
antigen
b
divergen
recent
immunosorb
assay
elisa
method
use
antigen
deriv
infect
hamster
cell
synthet
peptid
antigen
develop
format
advantag
potenti
autom
high
throughput
remain
primarili
research
tool
serolog
test
also
suffer
inabl
differenti
activ
past
infect
despit
low
parasitaemia
level
routin
observ
earli
acut
phase
reliabl
extrem
sensit
pcr
assay
design
amplifi
highli
conserv
sequenc
rrna
gene
babesia
spp
avail
pcr
assay
thu
use
identifi
patient
acut
phase
well
remain
persist
chronic
infect
said
pcr
assay
limit
somewhat
initi
sampl
volum
thu
neg
pcr
assay
alon
preclud
presenc
ongo
babesia
infect
alreadi
discuss
infect
b
microti
requir
drug
treatment
case
symptomat
diseas
persist
sever
drug
treatment
may
necessari
sinc
prefer
therapi
cours
clindamycin
quinin
gener
success
includ
tinnitu
gastroenter
occur
frequent
infect
may
persist
despit
treatment
altern
therapi
atovaquon
azithromycin
shown
equal
effect
reduc
advers
consequ
rare
instanc
drug
treatment
ineffect
high
level
parasitaemia
persist
sign
haemodynam
instabl
exist
exchang
transfus
may
prescrib
exchang
transfus
babesiosi
like
malaria
design
rapidli
reduc
overal
parasitaemia
level
relat
haemolysi
rare
procedur
shown
effect
case
babesiosi
especi
splenectom
patient
frequenc
babesia
spp
infect
human
popul
difficult
determin
precis
mention
previous
mani
infect
recogn
babesiosi
notifi
diseas
usa
moreov
systemat
seropreval
studi
publish
babesia
spp
determin
preval
blood
donor
rare
except
studi
usa
europ
northeast
usa
seropreval
b
microti
report
rang
connecticut
patient
lyme
diseas
sever
report
b
microti
blood
donor
publish
rate
high
posit
shelter
island
new
york
recent
connecticut
studi
report
blood
donor
seroposit
b
microti
perhap
importantli
seroposit
donor
studi
demonstr
parasitem
test
pcr
indic
obviou
transmiss
risk
sever
studi
report
seropreval
resid
northern
california
washington
rang
sacramento
california
blood
donor
show
evid
antibodi
rel
high
rate
particularli
area
parasit
endem
led
suggest
serolog
test
employ
studi
may
lack
specif
inde
accur
seropreval
measur
emerg
agent
requir
reliabl
assay
alway
readili
avail
european
studi
focus
b
divergen
b
microti
absenc
extens
studi
probabl
attribut
misconcept
babesia
infect
common
europ
observ
seropreval
rate
b
divergen
among
group
swedish
lyme
borreliosi
patient
small
studi
healthi
german
blood
donor
identifi
antibodi
b
microti
contrast
recent
german
studi
identifi
seropreval
rate
b
microti
b
divergen
respect
subpopul
healthi
blood
donor
within
latter
german
studi
includ
two
donor
antibodi
b
microti
one
donor
antibodi
b
divergen
establish
accur
estim
number
case
infect
babesia
spp
difficult
case
number
excess
routin
report
exact
number
increasingli
difficult
determin
mani
instanc
new
case
longer
report
publish
consist
basi
consid
novel
noteworthi
inde
knowledg
least
case
involv
b
microti
occur
usa
specif
inform
concern
case
wide
dissemin
creation
central
report
centr
babesia
spp
case
perhap
consid
way
monitor
extent
blood
safeti
threat
larg
major
case
howev
probabl
either
asymptomat
recogn
owe
natur
symptom
unfamiliar
physician
clinic
babesiosi
publish
case
involv
blood
recipi
rang
age
neonat
year
except
two
case
implic
attribut
b
microti
instanc
recipi
immunocompromis
sever
case
asplen
perhap
allow
case
easili
recogn
observ
incub
period
case
rang
week
report
case
occur
usa
except
one
case
canada
anoth
japan
japanes
case
implic
geograph
variant
b
microti
homolog
acquir
local
thought
maintain
nativ
field
mice
popul
contrast
canadian
case
involv
donor
appar
becam
infect
b
microti
usa
later
donat
infecti
unit
blood
upon
return
canada
case
highlight
potenti
donor
becom
infect
vacat
travel
area
case
infect
becom
increasingli
common
estim
transmiss
risk
avail
connecticut
studi
publish
determin
risk
transmit
b
microti
blood
transfus
prospect
measur
seroconvers
cardiothorac
surgeri
patient
risk
acquir
b
microti
unit
red
cell
report
confid
interv
ci
rate
platelet
unit
ci
recent
connecticut
studi
estim
risk
acquir
b
microti
transfus
red
cell
unit
estim
base
part
observ
seropreval
rate
area
connecticut
rate
demonstr
parasitemia
among
seroposit
donor
lookback
investig
yield
blood
recipi
infect
b
microti
blood
safeti
perspect
avail
option
prevent
reduc
transmiss
babesia
transfus
limit
time
summar
tabl
primari
risk
factor
acquir
babesia
spp
exposur
infect
tick
publish
studi
describ
abil
blood
donor
recal
recent
tick
exposur
howev
clear
correl
donor
abil
recal
tick
exposur
demonstr
babesia
infect
could
made
larg
sensit
question
low
inde
previous
mention
peopl
infect
diseas
recal
associ
tick
bite
contrast
serolog
assay
capabl
detect
babesia
spp
antibodi
would
appear
offer
reason
mean
identifi
infect
donor
interdict
potenti
infecti
blood
product
although
peopl
infect
b
divergen
ill
donat
blood
infect
b
microti
often
asymptomat
demonstr
strong
measur
antibodi
respons
last
month
year
follow
initi
infect
alreadi
discuss
ifa
elisa
format
babesia
exist
former
autom
latter
larg
development
natur
despit
issu
develop
serolog
test
b
microti
practic
feasibl
given
host
robust
immun
respons
sever
manufactur
offer
diagnost
assay
capabl
detect
igg
b
microti
howev
test
submit
much
less
licens
approv
us
food
drug
administr
b
microti
blood
screen
applic
usa
issu
surround
develop
test
b
microti
technic
scientif
natur
appear
associ
manufactur
percept
market
size
return
research
develop
invest
ongo
concern
whether
screen
actual
implement
inde
b
microti
remain
region
select
geograph
test
suggest
intervent
unfortun
region
approach
problemat
manufactur
perspect
rais
logist
issu
blood
collect
organ
perhap
larger
issu
transfus
medicin
commun
persuad
assay
manufactur
develop
test
agent
may
limit
market
econom
clearli
play
role
simpl
solut
problem
readili
avail
similarli
nat
would
feasibl
invalu
identifi
infect
cost
develop
assay
perceiv
limit
market
may
likewis
preclud
implement
blood
screen
await
develop
suitabl
test
altern
approach
manag
potenti
infecti
donor
propos
one
approach
avoid
blood
collect
highli
endem
area
period
peak
transmiss
ie
june
septemb
howev
report
persist
infect
blood
donor
suggest
select
blood
collect
would
partial
reduc
risk
transmiss
neg
impact
local
blood
avail
approach
includ
leucoreduct
filtrat
pathogen
reduct
pose
set
technic
barrier
leucoreduct
would
appear
ill
suit
babesia
spp
agent
contrast
filtrat
technolog
would
need
differenti
infect
red
cell
approach
howev
may
merit
infect
red
cell
probabl
present
differ
surfac
antigen
uninfect
cell
feasibl
technolog
reduc
inactiv
babesia
spp
alreadi
demonstr
regrett
host
respons
technolog
specif
involv
red
cell
recent
proven
problemat
lead
withdraw
system
market
remain
seen
technolog
hurdl
overcom
altern
approach
sometim
suggest
babesia
spp
one
pattern
use
limit
transmiss
cytomegaloviru
blood
recipi
greatest
risk
develop
sever
babesiosi
eg
elderli
asplen
individu
would
transfus
unit
blood
identifi
neg
babesia
spp
inde
immunocompet
blood
recipi
toler
babesia
infect
complic
elderli
asplen
develop
sever
even
diseas
approach
howev
predic
avail
approv
test
current
avail
newli
emerg
agent
continu
captur
attent
transfus
medicin
agent
babesia
spp
pose
ongo
seemingli
increas
threat
blood
safeti
perhap
receiv
inadequ
attent
part
lack
attent
may
caus
parasit
limit
geograph
distribut
mild
diseas
experienc
patient
howev
distribut
babesia
spp
appear
greater
origin
thought
parasit
increasingli
implic
case
particularli
among
patient
receiv
larg
amount
blood
highli
suscept
babesi
infect
eg
elderli
asplen
immunocompromis
lack
consensu
approach
prevent
transmiss
babesia
spp
remain
problemat
may
easili
resolv
absenc
licens
blood
screen
test
one
greatest
hurdl
address
babesia
spp
persuad
manufactur
develop
approach
particularli
screen
assay
perceiv
limit
market
overcom
obstacl
concert
effort
among
govern
agenc
blood
collect
organ
public
health
commun
need
encourag
develop
suitabl
intervent
babesia
spp
summari
babesia
spp
clearli
visibl
radar
screen
appropri
intervent
consid
order
reduc
blood
safeti
risk
pose
agent
